NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Eascra Biotech

Eascra Biotech

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://eascrabiotech.com/

Last Round

Grant

Mar 25, 2026

Total Funding Raised

$2.35M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Eascra Biotech is a biotechnology company that provides a nanomedicine platform for precision therapeutic delivery to hard-to-penetrate tissues like articular cartilage, kidneys, and solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

extracellular vesiclesEV therapeuticsdrug delivery techdrug delivery platformJanus base nanoparticlesnanomedicineJBNpregenerative medicinebiological transportbiotech startupbiotech R&Ddeep tech biotechtherapeutic payloadspace manufacturingnon-dilutive funding

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Eascra Biotech Comps

Public and private peers based on sector, stage, and business model.

Eascra Biotech comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Eascra Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 25, 2026
AcceleratorJul 24, 2025
GrantMay 19, 2025
GrantApr 21, 2025
GrantMar 7, 2025
Grant
Mar 7, 2025

Key People

Founding team and executive leadership

Mari Anne Snow

CEO, Co-founder

Founding Team

Eascra Biotech Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 28, 2026

    Grew 60% QoQ from 5 to 8 employees.

  • Mar 10, 2026

    Attended TechConnect World Innovation Conference and Expo in Raleigh, NC.

Eascra Biotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Eascra Biotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Eascra Biotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range8
Year Founded2021
Last FundingMar 25, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.